DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Marksans Pharma Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 1 hr ago·13 Oct 2026, 8:33 am

Marksans Pharma

Marksans Pharma Limited has informed the stock exchanges that it has filed the required compliance certificate under SEBI regulations for the quarter and half-year ended September 30, 2026. This document confirms that the company has complied with the regulatory obligations related to its shareholding pattern and depository operations during this period.

For investors, this filing is a routine corporate disclosure that indicates the company is maintaining proper compliance with market regulations. It does not reflect on the company's operational performance or financial health but serves as a standard administrative update to ensure transparency with the market.

Investors should watch for the official filing on the exchange to verify the details. Since this is a standard regulatory requirement, it is generally considered a neutral event with no immediate impact on the stock price.